Profile data is unavailable for this security.
About the company
Ocumension Therapeutics is a China-based holding company principally involved in the discovering, developing and commercializing ophthalmic therapies. Its main products include OT-401 (YUTIQ), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-301 (NCX 470), OT-101 and OT-202, among others. The Company conducts its businesses in the domestic market.
- Revenue in HKD (TTM)341.48m
- Net income in HKD-355.16m
- Incorporated2018
- Employees477.00
- LocationOcumension TherapeuticsNo. 1858 Yinzhongnan RoadGuoxiang Subdistrict, Wuzhong DistrictSUZHOU KY1-1205ChinaCHN
- Websitehttps://www.ocumension.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dawnrays Pharmaceutical (Holdings) Ltd | 1.19bn | 619.69m | 1.68bn | 1.18k | 2.72 | 0.4673 | 2.40 | 1.42 | 0.4125 | 0.4125 | 0.7903 | 2.40 | 0.2838 | 2.05 | 6.17 | 1,038,556.00 | 14.74 | 9.89 | 17.79 | 12.49 | 56.58 | 56.69 | 51.92 | 27.89 | 3.04 | -- | 0.0544 | 35.33 | -9.90 | 3.94 | -8.95 | 1.41 | 63.92 | 2.00 |
Cryofocus Medtech Shanghai Co Ltd | 45.68m | -116.93m | 1.81bn | 370.00 | -- | 13.94 | -- | 39.57 | -0.489 | -0.489 | 0.191 | 0.5422 | 0.1881 | 0.418 | 4,369.58 | 116,537.00 | -51.79 | -- | -66.30 | -- | 76.35 | -- | -275.28 | -- | 2.06 | -50.20 | 0.2303 | -- | 50.83 | -- | 13.13 | -- | -- | -- |
Golden Throat Holdings Group Co Ltd | 1.11bn | 288.56m | 2.29bn | 860.00 | 7.94 | 1.62 | 6.92 | 2.07 | 0.3903 | 0.3903 | 1.50 | 1.91 | 0.4994 | 3.23 | 4.07 | 1,274,300.00 | 13.01 | 11.00 | 19.26 | 15.63 | 72.29 | 72.79 | 26.06 | 24.67 | 1.93 | 37.74 | 0.2814 | 83.15 | -3.09 | 6.73 | -11.04 | 19.61 | -32.13 | 38.94 |
Ocumension Therapeutics | 341.48m | -355.16m | 3.09bn | 477.00 | -- | 1.03 | -- | 9.05 | -0.5419 | -0.5419 | 0.5208 | 4.39 | 0.103 | 2.40 | 2.48 | 769,089.90 | -10.71 | -38.78 | -11.55 | -41.47 | 58.29 | 62.30 | -104.01 | -975.82 | 5.00 | -- | 0.0055 | -- | 54.99 | -- | 5.68 | -- | 319.66 | -- |
Cutia Therapeutics | 218.84m | -577.04m | 4.28bn | 360.00 | -- | 3.27 | -- | 19.54 | -1.90 | -1.90 | 0.719 | 4.30 | 0.1206 | 2.31 | 6.93 | 734,356.40 | -31.81 | -- | -35.82 | -- | 50.33 | -- | -263.68 | -- | 4.82 | -- | 0.1818 | -- | 1,110.83 | -- | -253.30 | -- | -- | -- |
Jiangsu Recbio Technology Co Ltd | 0.00 | -603.67m | 4.30bn | 507.00 | -- | 4.63 | -- | -- | -1.26 | -1.26 | 0.00 | 1.92 | 0.00 | -- | -- | 0.00 | -25.33 | -- | -32.84 | -- | -- | -- | -- | -- | 0.9619 | -60.96 | 0.4548 | -- | -- | -- | 20.86 | -- | -- | -- |
Beijing Luzhu Biotechnology Co Ltd | 0.00 | -308.07m | 4.52bn | 148.00 | -- | 4.38 | -- | -- | -1.52 | -1.52 | 0.00 | 5.13 | 0.00 | -- | -- | 0.00 | -23.80 | -- | -25.44 | -- | -- | -- | -- | -- | 5.91 | -- | 0.0296 | -- | -- | -- | 65.62 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to Ocumension Therapeutics's reporting currency: Hong Kong Dollar HKD
Holder | Shares | % Held |
---|---|---|
Temasek Holdings Pte Ltd. (Investment Management)as of 26 Aug 2024 | 41.31m | 5.96% |
Capital Research & Management Co. (World Investors)as of 06 Dec 2023 | 34.37m | 4.95% |
Zhong Geng Fund Management Co. , Ltd.as of 31 Dec 2023 | 21.38m | 3.08% |
The Vanguard Group, Inc.as of 04 Sep 2024 | 9.36m | 1.35% |
Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 4.99m | 0.72% |
Capital Research & Management Co. (Global Investors)as of 30 Jun 2024 | 3.10m | 0.45% |
Dimensional Fund Advisors LPas of 05 Sep 2024 | 2.72m | 0.39% |
FIL Investment Management (Hong Kong) Ltd.as of 31 Jul 2024 | 2.60m | 0.38% |
E Fund Management Co., Ltd.as of 31 Dec 2023 | 2.14m | 0.31% |
UBS Asset Management (Hong Kong) Ltd.as of 31 May 2024 | 2.04m | 0.29% |
More ▼
Data from 31 Dec 2023 - 12 Sep 2024Source: FactSet Research Systems Inc.